Last reviewed · How we verify
NCT03041207: VAIN2
Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection
trial testing Development and implementation of an antibiotic guideline in Ventilator Associated Pneumonia in 555 participants. Completed in 30 April 2019.
30 April 2019
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 555 |
| Start date | 20 March 2017 |
| Primary completion | 30 April 2019 |
| Estimated completion | 30 April 2019 |
| Sites | 23 locations across Canada, United States |
Drugs / interventions tested
- Development and implementation of an antibiotic guideline
Conditions studied
- Ventilator Associated Pneumonia — all drugs for Ventilator Associated Pneumonia →
- Nosocomial Infections in Children — all drugs for Nosocomial Infections in Children →
- Microbial Colonization — all drugs for Microbial Colonization →
Sponsor
Virginia Commonwealth University
Who can join
Under 3, any sex, with Ventilator Associated Pneumonia or Nosocomial Infections in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective study with three specific aims: (1) To convene a consensus conference to develop a guideline for antibiotic use in infants (age \< 3 yrs) with suspected ventilator-associated infection; (2) To evaluate outcomes before and after implementation of the antibiotic guideline; (3) To evaluate changes in the tracheal microbiome over the course of mechanical ventilation
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03041207
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ventilator Associated Pneumonia
Currently open trials in the same condition.
- NCT07102407 — Effect of a Constructivist Educational Program on Preventing Ventilator-Associated Pneumonia in Intensive Care Units · NA · recruiting
- NCT06554327 — Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens · NA · recruiting
- NCT05591924 — Early Severe Illness TrAnslational BioLogy InformaticS in Humans · recruiting
- NCT06092554 — Probiotics to Actively Counter Ventilator Associated Pneumonia (PROACT) · NA · recruiting
- NCT05979545 — EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics · Phase 4 · recruiting
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03041207 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 17 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03041207.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing